Exagen Inc.

XGN

US30068X1037

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
1.95 ^USD	+1.56%		+4.84%	-2.01%

14/05	Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating	MT
13/05	Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Exagen Inc. Announces Resignation of Chet Burrell from the Board, Effective December 31, 2020

November 11, 2020 at 02:42 am IST

On November 6, 2020, Chet Burrell informed the Board of Directors of Exagen Inc. of his decision to resign from the Board, effective December 31, 2020.

Latest news about Exagen Inc.

Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating	14/05	MT
Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
Transcript : Exagen Inc., Q1 2024 Earnings Call, May 13, 2024	13/05
Earnings Flash (XGN) EXAGEN Reports Q1 Revenue $14.4M, vs. Street Est of $13.1M	13/05	MT
Exagen Inc. Updates Earnings Guidance for the Full Year 2024	13/05	CI
Exagen Inc. Announces Changes in Board of Directors	26/04	CI
Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03	CI
Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $13.8M, vs. Street Est of $11.6M	18/03	MT
Transcript : Exagen Inc., Q4 2023 Earnings Call, Mar 18, 2024	18/03
Exagen Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	18/03	CI
Exagen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03	CI
North American Morning Briefing : Investors -2-	18/03	DJ
Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023	07/01	CI
Exagen Files $150 Million Mixed Shelf	20/11	MT
Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Transcript : Exagen Inc., Q3 2023 Earnings Call, Nov 13, 2023	14/11
Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $13.4M, vs. Street Est of $10.3M	14/11	MT
Exagen Reaches Settlement With US Department of Justice Over Alleged Kickbacks to Promote Lab Test Use	18/23/18	MT
Exagen Reaches Settlement With US Department of Justice Over Alleged Kickbacks to Promote Lab Test Use	18/23/18	MT
Exagen Agrees to Pay Over $650K to Resolve Kickback Allegations	18/23/18	DJ
Transcript : Exagen Inc., Q2 2023 Earnings Call, Aug 07, 2023	07/23/07
Earnings Flash (XGN) EXAGEN Reports Q2 Revenue $14.1M, vs. Street Est of $10.9M	07/23/07	MT
Exagen Inc. Provides Revenue Guidance for the Third Quarter of 2023	07/23/07	CI
Exagen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/23/07	CI
North American Morning Briefing : Investors Await -2-	07/23/07	DJ

Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.

Sector

Healthcare Facilities & Services

Calendar

10/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Exagen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.95 USD

Average target price

5.5 USD

Spread / Average Target

+182.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
EXAGEN INC.	-2.01%	33.88M
HCA HEALTHCARE, INC.	+25.52%	88.99B
CVS HEALTH CORPORATION	-24.52%	74.82B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+0.92%	26.63B
FRESENIUS SE & CO. KGAA	+4.88%	17.88B
LABCORP HOLDINGS INC.	-14.25%	16.43B
QUEST DIAGNOSTICS INCORPORATED	+2.97%	15.77B
TENET HEALTHCARE CORPORATION	+79.20%	13.21B
NATERA, INC.	+70.11%	13.08B
DAVITA INC.	+40.44%	12.9B

Other Healthcare Facilities & Services

Exagen Inc.

Equities

XGN

US30068X1037

Healthcare Facilities & Services

Exagen Inc. Announces Resignation of Chet Burrell from the Board, Effective December 31, 2020

Latest news about Exagen Inc.

Chart Exagen Inc.

Company Profile

Income Statement Evolution

Ratings for Exagen Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Healthcare Facilities & Services